Wells Fargo Maintains Equal-Weight on Cellectis, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Neutral 73.1%

Neg 0% Neu 73.1% Pos 0%

Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers the price target from $4 to $3.